The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in partici…

CancerColorectal CancerSolid Tumor+12 more

~Estimated

~$10 – $8,750

Parabilis Medicines, Inc.NCT05919264

Phase 2

Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (Tocilizumab) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma

ACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) J…

Adamantinomatous CraniopharyngiomaRecurrent Adamantinomatous Craniopharyngioma

~Estimated

~$10 – $6,250

Nationwide Children's HospitalNCT05233397

Phase 2

Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biolo…

Adamantinous CraniopharyngiomaRecurrent Adamantinomatous Craniopharyngioma

~Estimated

~$10 – $6,250

Nationwide Children's HospitalNCT05286788